Dr Lars Linden | Head of Protein Biochemistry
Bayer AG

Dr Lars Linden, Head of Protein Biochemistry, Bayer AG

Biologics, Cell and Protein Sciences – Protein Biochemistry 
Lars Linden is Head of the Protein Biochemistry group in Biologics Research at Bayer and responsible for production of research compounds and tools for biologics projects of Bayer’s early research pipeline. He is also overseeing developability assessments for lead candidates.
Lars joined Bayer in 2007 during the acquisition of Schering AG as a lab head in protein biochemistry. 
Previously he worked in crystallization of GPCRs and ion channels in a small biotech company “m-phasys”.
Lars received his PhD in biochemistry for his work on structural biology/ X-ray crystallography of plant proteins in the group of Prof. Robert Huber at the Max-Planck Institute for Biochemistry   


EAC 2017 Day 2, Wednesday 1st November 2017 @ 18:00

Developability: looking for “drug like properties” right from the start

  • How to address developability early on in lead discovery 
  • In silico and higher throughput in vitro methods
  • Developability in LO Phase and specialties for ADCs

back to speakers